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Abstract
Costimulatory pathways (Cluster of differentiation 
28, tumor necrosis factor-related, adhesion and T 
Cell Ig- and mucin-domain molecules) regulating the 
interactions between receptors on the T cells and 
their ligands expressed on several cell types, have a 
key role in controlling many immunological and non 
immunological processes. Indeed, accumulating evidence 
indicate that these molecules are involved in the patho-
genesis of numerous conditions, such as allograft rejec-
tion, atherosclerosis, rheumatoid arthritis, psoriasis and 
renal diseases, including glomerulonephritis. Primary 
or secondary (i.e. , associated with infections, drugs or 
systemic diseases, such as systemic lupus erythematosus, 
diabetes, etc .) glomerulonephritis represent a group 
of heterogeneous diseases with different pathogenic 
mechanisms. Since costimulatory molecules, in particular 
CD80 and CD40, have been found to be expressed 
on podocytes in the course of different experimental 
and clinical glomerulonephritis, costimulation has been 
thought as a new therapeutic target for patients with 
glomerular diseases. However, although experimental 
data suggested that the blockade of costimulatory 
pathways is effective and safe in the prevention and 
treatment of glomerular diseases, clinical trials reported 
contrasting results. So, at this moment, there is not a 
strong evidence for the general use of costimulatory 
blockade as an alternative treatment strategy in patients 
with primary or secondary glomerulonephritis. Here, we 
critically discuss the current data and the main issues 
regarding the development of this innovative therapeutic 
approach.
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Core tip: Glomerulonephritis refer to a group of renal 
disorders, primary or secondary to infections, drugs or 
systemic diseases, characterized by inflammation within 
the glomerulus. Among glomerular diseases there is a 
great clinical, histological and prognostic heterogeneity 
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and several different pathogenetic mechanisms have been 
implied. Current standard treatments include steroids 
and cytotoxic agents, which present important side 
effects and an unsatisfactory remission rate. Therefore, 
experimental and clinical research is addressed to the 
development of alternative therapies. Here, we critically 
discuss new therapeutic opportunities provided by the 
use of agents acting on the modulation of costimulatory 
pathways.
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COSTIMULATORY PATHWAYS
Costimulatory pathways regulating the interactions 
between receptors on the T cells and their ligands 
expressed on several cell types (including immunocom­
petent cells, fibroblasts, endothelial cells, etc.) play a 
crucial role in the modulation of immunological and non­
immunological processes[1].
In particular, costimulation is essential for the full 
activation of naïve T cells after antigen-specific recogni-
tion, and without costimulation the T cell­antigen intera­
ction results in anergy[2].  
Different costimulatory families [Cluster of differen­
tiation 28 (CD28), tumor necrosis factor (TNF)­related, 
adhesion and T Cell Ig­ and mucin­domain (TIMs) 
molecules], characterized by structural and functional 
analogies, have been described. These molecules can 
interact with each other either up­ or down­regulating T 
cell activation[3] (Table 1). 
Among the identified costimulatory molecules, the 
best characterized are the CD28:B7 and the TNF­related 
families. The CD28:B7 family includes the following 
receptor­ligand pairs: CD28/CTLA4:CD80/CD86, 
induced costimulatory molecules (ICOS:ICOSL) and the 
programmed death­1 pathway (PD­1:PD­L1/PD­L2)[4]. 
CD28 is a disulfide­bound molecule that belongs to 
the immunoglobulin superfamily and is constitutively 
expressed on T cells[5]. 
Its interaction with CD80 (B7.1) and CD86 (B7.2), 
expressed on the surface of antigen­presenting cells 
(APCs), leads to the full activation of T cells[6]. Conver­
sely cytotoxic T­lymphocyte­associated antigen­4 
(CTLA4), a structural homologous of CD28 with a higher 
avidity for CD80 and CD86, acts as a negative regulator 
of T cells[7]. 
TNF superfamily comprises: CD40:CD40L, OX40:
OX40L, CD30:CD30L, CD27:CD70, CD137:CD137L, 
etc. CD40 is mainly expressed on B­cells, but also on 
monocytes, dendritic cells, endothelial cells, smooth 
muscle cells and fibroblasts[8]. The engagement of 
CD40 with its ligand, CD40L (CD154), leads to B cell 
expansion and differentiation and it is decisive in the 
regulation of APCs and dendritic cells functions[9]. It is 
important to underline that costimulatory molecules, 
expressed by a broad variety of cells, seem to be 
involved in the pathogenesis of numerous conditions, 
such as atherosclerosis, rheumatoid arthritis, psoriasis 
and renal diseases, including allograft rejection and 
glomerulonephritis[10­14].
The insights regarding the contribution the costimu­
latory molecules in these conditions has not only 
allowed elucidating important regulatory mechanisms, 




Glomerulonephritis refer to a group of renal disorders, 
primary or secondary to infections (human immuno­
deficiency virus, hepatitis C virus, etc.), drugs and 
systemic diseases (for example, systemic lupus erithema­
tosus­SLE, cancer and diabetes), characterized by 
inflammation within the glomerulus[16].
Among glomerular diseases there is a great clinical, 
histological and prognostic heterogeneity and several 
different pathogenic mechanisms are implied, including 
podocyte damage, immunoglobulin deposition and 
immune cell infiltration[17]. During the last years growing 
evidence suggest a role for costimulatory molecules also 
in this specific setting. 
In particular, CD80 expression has been detected 
in podocytes, which integrity is essential to maintain a 
regular glomerular function[18].
Indeed, in experimental models of genetic, drug­
induced, immune­mediated and bacterial toxin­induced 
kidney diseases, CD80 overexpression on podocytes 
might be harmful for glomerular permeability, disturbing 
the slit diaphragm and down­regulating podocytes­β1 
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Table 1  Immunomodulatory effects of costimulation pathways
  Family Ligand Receptor Effects on 
immune cells






  TNF-related CD40 CD40L (CD154) +
OX-40 OX-40L +
  Adhesion 
  molecules
ICAM-1 LFA-1 +
  TIM TIM4/9 TIM1/3 +/-
Costimulatory pathways may influence immune response through stimu­
latory (+) or inhibitory (-) signals. Ligands may be present on antigen-
presenting cells, including B-lymphocytes and dendritic cells, but also on 
muscle, endothelial, fibroblast, platelets and epithelial­derived cells. Receptors 
are mainly expressed on T-cells[48]. CTLA-4: Cytotoxic T-lymphocyte-
associated antigen-4; ICOS: Induced costimulatory molecule; PD-1: 
Theprogrammeddeath-1; LFA-1: Lymphocyte function-associated antigen 1; 
ICAM-1: Intracellular adhesion molecule 1; TIM: T cell Ig and mucin.
integrin activation, finally leading to the development 
of proteinuria and loss of renal function[19,20]. The crucial 
role of CD28:CD80 pathway in the pathogenesis of 
glomerular diseases is also confirmed by the evidence 
that CD80 knockout mice present an attenuated form 
of proliferative glomerulonephritis, associated with a 
significant reduction of renal tissue lesions[21]. 
Moreover, the use of monoclonal antibodies targe­
ting CD28 or CTLA­4 was effective in treating and 
preventing different forms of experimental nephritis, 
including lupus­like nephritis[22]. Interestingly, similar 
results were also found in human glomerulonephritis. 
In particular, a significant increase in CD80 podocyte 
expression and urinary excretion has been reported in 
patients with minimal change disease (MCD) in relapse 
compared to those in remission or with focal segmental 
glomerulosclerosis (FSGS)[23,24]. Similarly, patients with 
proliferative lupus nephritis present a strong podocyte 
surface expression of CD80[20]. 
Beyond CD28:CD80 pathway, also costimulatory 
molecules of TNF­related family, i.e., CD40:CD154, 
have been found expressed in renal tissue in the course 
of both experimental and human glomerular diseases. 
CD40 was isolated in murine models of proteinuric 
disease, such as membranous glomerulonephritis, 
lupus nephritis and necrotizing nephritis[25]. Moreover, 
glomerular and tubular CD40 expression was up­
regulated in human lupus nephritis and in other inflam-
matory renal diseases, being associated with the 
presence of CD40L+ mononuclear cells[26]. Furthermore, 
the inhibition of CD40 pathway through the adminis­
tration of a CD40­Ig fusion protein or anti­CD40L antibo­
dies prevented the development of proteinuric kidney 
diseases in mice[27,28]. 
COSTIMULATORY BLOCKADE 
AS A NOVEL TREATMENT FOR 
GLOMERULONEPHRITIS
As a consequence of the role of costimulation in the 
pathogenesis of several pathological conditions, 
costimulatory blockade has been thought as a new 
rational therapeutic approach[29]. Therefore different 
strategies, mainly based on the design of specific 
monoclonal antibodies (mAbs) interfering with these 
critical pathways, have been tested. However, the clinical 
development of the majority of these new strategies is 
currently suspended for safety concerns.
This is, for example, the case of anti­CD40L mAb, 
which although effective in the prevention of glomerular 
diseases and renal allograft rejection in murine and 
primate experimental models, significantly increased 
the occurrence of thromboembolic events[27,30­32]. More 
severe complications occurred during the development 
of anti­CD28 mAbs. Indeed, six healthy volunteers 
enrolled in a phase I clinical trial and treated with a 
humanized superagonistic anti­CD28 mAb, developed a 
life-threatening systemic inflammation due to massive 
cytokine release, determining the complete abandon of 
this approach[33]. A more promising strategy­ the only 
one that has found clinical applications so far­ seems to 
be the development of CTLA­4 immunoglobulin fusion 
proteins. These proteins are composed by an extra­
cellular portion of human CTLA4 plus a Fc part of human 
IgG1, which, binding CD80 and C86 with high avidity, 
prevent CD28 ligation, acting as potent inhibitors of 
CD28:CD80/CD86 pathways[34,35]. Abatacept, which has 
been approved by FDA for the treatment of rheumatoid 
arthritis in 2005, and its derivate, Belatacept, belong to 
this category of drugs. 
Belatacept has been extensively studied mainly in 
the experimental and clinical setting of renal transplan­
tation. 
Belatacept was evaluated in 2 open­label, rando­
mized, multicenter, controlled phase 3 studies: the 
Belatacept Evaluation of Nephroprotection and Efficacy 
as First­line Immunosuppression Trial (BENEFIT) and 
BENEFIT­EXT (“extended criteria”).
These studies showed that Belatacept was non­
inferior to Cyclosporine in terms of patient and graft 
survival, being associated to a better graft function and 
a reduced incidence of chronic nephropathy[36,37]. Hence, 
although the administration of belatacept was not 
exempt from adverse effects, in 2011 it was approved 
by Food and Drug Administration (FDA) as the first 
costimulatory blocker for use in renal transplantation[38].
Regarding the specific setting of primary and secon-
dary glomerulonephritis, instead, only Abatacept has 
been used in clinical studies with discordant results.
Two recent randomized trials investigated the 
safety and efficacy of Abatacept in addition to standard 
treatments in patients with lupus nephritis.
A twelve months blind multicentre trial, performed 
by Furie et al[39], enrolled 298 patients with active 
lupus nephritis and proteinuria, randomized to receive 
corticosteroids and Mycophenolate mofetil in association 
with Abatacept (30 mg/kg loading for 3 mo, followed 
by 10 mg/kg), Abatacept (10 mg/kg) or placebo. The 
authors found that the treatment with Abatacept was 
associated with a reduction of antiDNA antibody, C3 
and C4 levels and proteinuria. However, there were not 
significant differences in the time to reach a complete 
response and in the proportion of subjects with con­
firmed complete response after 52 wk of follow­up 
among the three groups. 
Similar results have been reported by Askanase 
et al[40] who evaluated the efficacy of Abatacept vs 
placebo added to a standard treatment regimen with 
Cyclophosphamide followed by Azathioprine in 134 
patients with active lupus nephritis. They also found 
no significant differences between the groups in terms 
of number of patients reaching and/or maintaining 
complete or partial response.
So, even if previous studies reporting the strong 
expression of podocyte CD80 in human proliferative 
lupus nephritis appeared promising, the results of these 
clinical trials have unexpectedly called into question the 
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targets and disease remission.  
So, it appears clear that further molecular, cellular 
and clinical studies, including the design and evaluation 
of new drugs and exploration of new pathways, should 
be performed before considering costimulatory blockade 
as a valid alternative treatment in the general popula­
tion of patients with glomerulonephritis.
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